Muhammad Mukhlis

Muhammad Mukhlis

Auto-generated profile, based on publicly available information

Muhammad Mukhlis

Ayub Medical College, Abbottabad, Pakistan

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2026 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
MZMohammad A. Zaied
Mohammad A. Zaied
MSMuhammad Shahzaib
Muhammad Shahzaib
MMMuhammad Mukhlis
Muhammad Mukhlis
JLJaveria Latif
Javeria Latif
NFNoor Fatima
Noor Fatima
PSPranjal Singh
Pranjal Singh

23 September 2026 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
EAEshal Atif
Eshal Atif
AAAbdal Ahmad
Abdal Ahmad
MAMazhar Ali
Mazhar Ali
MHMohib Ali Hassan
Mohib Ali Hassan
VDVishan Das
Vishan Das
AOAkef Obeidat
Akef Obeidat
Type 2 diabetes mellitus (T2DM) is a major contributor to premature illness and death in the United States. Prevalence is well tracked, but demographically

9 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
HAHassaan Abid
Hassaan Abid
SMSohana Memon
Sohana Memon
VDVishan Das
Vishan Das
THTauseef Hamid
Tauseef Hamid
KFKaneez Fatima
Kaneez Fatima
RKRithik Kumar Khiani
Rithik Kumar Khiani
Background: Coronary artery disease (CAD) and depression frequently coexist and may synergistically worsen outcomes through behavioral, inflammatory, and neuroendocrine mechanisms. However, national mortality trends involving both conditions remain incompletely characterized.Objective: To evaluate temporal trends and demographic disparities in mortality involving CAD and depression in the United States from 1999–2025.Methods: We conducted a retrospective population-based study using the CDC WONDER Multiple Cause of Death database. Adults aged ≥25 years with ICD-10 codes for CAD (I20–I25) and depression (F32, F33, F41.2) listed anywhere on the death certificate were identified. Age-adjusted mortality rates (AAMRs) per 100,000 population were standardized to the 2000 U.S. population. Joinpoint regression was used to estimate annual percent change (APC) and average annual percent change (AAPC), with analyses stratified by age, sex, race/ethnicity, geographic region, urbanization, and state.Results: A total of 85,806 deaths were identified, with an overall average AAMR of 1.42. Mortality declined from 1.81 (95% CI, 1.75–1.87) in 1999 to 1.31 (95% CI, 1.26–1.35) in 2025 (AAPC, −1.38; p=0.002), although rates increased significantly between 2017 and 2020. Mortality was highest among older adults but increased among middle-aged adults (AAPC, 1.10; p<0.001). Males had higher mortality than females. The Midwest had the highest regional burden, while the South showed no significant overall improvement. Mortality increased among Black individuals after 2014 and remained higher in nonmetropolitan areas.Conclusions: Mortality involving CAD and depression declined overall but remained heterogeneous, with persistent racial and geographic disparities and rising mortality among middle-aged adults.

13 August 2026 in BMC Gastroenterology
Verified
Journal Article
Open access
EAEshal Atif
Eshal Atif
VDVishan Das
Vishan Das
AAAbdul Moeez Awais
Abdul Moeez Awais
KFKaneez Fatima
Kaneez Fatima
Sadia QaziSadia Qazi
Sadia Qazi
AOAkef Obeidat
Akef Obeidat

8 October 2026 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
VDVishan Das
Vishan Das
APAmna Parvez
Amna Parvez
Sadia QaziSadia Qazi
Sadia Qazi
KFKaneez Fatima
Kaneez Fatima
MMMuhammad Mukhlis
Muhammad Mukhlis
MKMuhammad Hanif Khan
Muhammad Hanif Khan
Introduction: Chronic lower respiratory disease (CLRD) and dementia are the leading causes of death among older US adults and frequently coexist; however, their combined mortality burden is uncharacterized nationally. We examined the trends and disparities in deaths involving both. Methods: We analyzed 1999–2023 US multiple cause-of-death data from the CDC WONDER for decedents aged ≥ 65 years with both CLRD (ICD-10 J40–J47) and dementia (F01, F03, G30–G31) listed anywhere on the certificate. Age-adjusted mortality rates (AAMRs) per 100,000 were calculated overall and by sex, race/ethnicity, census region, urbanization, and place of death; crude rates (CMRs) were used for age strata. Joinpoint regression gave annual and average annual percent changes (APCs, AAPCs). Results: Among 557,547 deaths, the overall AAMR rose from 29.50 per 100,000 in 1999 to 55.69 in 2023, peaking at 65.70 in 2020 (AAPC: 2.64; 95% CI: 0.93–4.39; p = 0.002). Men had a higher mean AAMR than women (57.58 vs. 47.29), but only women rose significantly (AAPC: 3.66; p < 0.001 vs. 1.42; p = 0.128); the male-to-female ratio fell from 1.62 to 0.97, with women overtaking men by 2023. The mean AAMRs were 55.07 in non-Hispanic (NH) White (AAPC: 3.02; p = 0.0004), 40.56 in NH Black (2.70; p = 0.035), 32.47 in Hispanic (1.20; p = 0.001), and 20.42 in NH Asian or Pacific Islander adults (3.13; p = 0.206); and 55.18 in the South (2.80; p < 0.001), 54.84 in the Midwest (3.02; p = 0.004), 51.19 in the West (2.53; p = 0.005), and 39.60 in the Northeast (1.91; p = 0.065). Non-metropolitan AAMRs exceeded metropolitan AAMRs (61.70 vs. 47.61; AAPC: 4.12; p < 0.001 vs. 2.85; p = 0.008), with the gap widening from 5.0 to 22.6. 2023 CMRs were 243.83 (≥ 85 years; AAPC: 3.19; p = 0.001), 59.36 (75–84; 2.38; p = 0.011) and 8.98 (65–74; 2.80; p = 0.019). Nursing home deaths fell from 58.2% to 43.3% as home deaths rose to 28.0% and hospice deaths to 7.9%. Conclusion: Mortality involving coexisting CLRD and dementia in older US adults nearly doubled from 1999 to 2023, shifting toward women, non-metropolitan residents, and the very old, while end-of-life care moved from hospitals and nursing homes into homes and hospices.

8 October 2026 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
PDF file
AGAnika Goel
Anika Goel
MNMuhammad Abdullah Naveed
Muhammad Abdullah Naveed
HTHemeesh Tandel
Hemeesh Tandel
AMAffaf Mahmood
Affaf Mahmood
MMMuhammad Mukhlis
Muhammad Mukhlis
HTHaris Bin Tahir
Haris Bin Tahir
Background: Atherosclerotic cardiovascular disease is a leading cause of morbidity and mortality, and many high‐risk patients fail to reach LDL‐cholesterol (LDL‐C) targets on statins alone. Evolocumab, a PCSK9 inhibitor, offers potent LDL‐C lowering, but a synthesis of its lipid and clinical benefits in secondary prevention is needed. Methods: We conducted a systematic review and meta‐analysis of randomised controlled trials evaluating evolocumab in adults with established cardiovascular disease. PubMed, Embase, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov were searched through April 2025. Outcomes included lipid parameters, major adverse cardiovascular events (MACE), individual cardiovascular endpoints, and safety, with pooled risk ratios (RR) and mean differences calculated using random‐effects models. Results: Nine trials enrolling 67,662 patients were included. Evolocumab significantly reduced LDL‐C (mean difference −57.73 mg/dL), total cholesterol (−52.27 mg/dL), triglycerides (−21.21 mg/dL), and lipoprotein(a) (−10.99 mg/dL), while increasing HDL‐cholesterol (3.69 mg/dL). Evolocumab was associated with lower MACE (RR 0.53; 95% CI 0.40–0.71), though this estimate should be interpreted cautiously given heterogeneity in endpoint definitions and study designs. Myocardial infarction (RR 0.74) and coronary revascularisation (RR 0.80) were significantly reduced, while cardiovascular mortality and stroke showed no statistically definitive reduction. Serious adverse events and neurocognitive effects were comparable between groups, though injection‐site reactions were more frequent with evolocumab. Conclusion: In patients with established cardiovascular disease, evolocumab provides substantial lipid lowering and reduces ischemic events without major safety concerns, supporting its use as an adjunct to statin therapy in secondary prevention.